Human Anti-ERBB3 Recombinant Antibody (clone KTN3379) (CAT#: PABL-086)

Recombinant Human Antibody (KTN3379) is capable of binding to ERBB3, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-ERBB3 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-ERBB3 mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. The inhibitory ErbB3 antibody blocks both NRG-dependent and-independent mechanisms of activation by binding to a novel epitope.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 HPV+ HNSCC models are sensitive to therapeutic blockade of HER3 with the anti-HER3 monoclonal antibody, KTN3379.

Figure 1 HPV+ HNSCC models are sensitive to therapeutic blockade of HER3 with the anti-HER3 monoclonal antibody, KTN3379.

A, HPV− and HPV+ HNSCC cell lines were treated with 100 nmol/L KTN3379 for 72 hours before performing proliferation assays. Proliferation is plotted as a percentage of growth relative to vehicle-treated cells (n = 6 in three-five independent experiments). Data points are represented as mean ± SEM. Whole-cell lysates were harvested from three HPV− cell lines (PECAPJ49, TU138, and SCC1), and three HPV+ cell lines (SCC47, 93-VU-147T, and SCC90) over a time course of 72 hours of KTN3379 treatment (100 nmol/L) followed by immunoblotting for the indicated proteins. β-Actin was used as a loading control. B, HPV+ cell lines (SCC47 and SCC90) were grown as xenografts in athymic nude mice (n = 6 tumors per treatment group for SCC47, and n = 4 tumors per treatment group for SCC90). The HPV+ PDX-10 was implanted into the dorsal flanks of NOD/SCIDγ mice (n = 6 tumors per treatment group). All xenografts were treated with KTN3379 (10 mg/kg) or vehicle twice weekly for the indicated time period by IP injection.

Brand, T. M., Hartmann, S., Bhola, N. E., Peyser, N. D., Li, H., Zeng, Y.,... & LaVallee, T. M. (2017). Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV+ patients. Clinical Cancer Research, 23(12), 3072-3083.

Figure 2 KTN3379 inhibits HER3 signaling and tumor growth in HER2-amplified cancer cells.

Figure 2 KTN3379 inhibits HER3 signaling and tumor growth in HER2-amplified cancer cells.

A: BT474 cells were treated with the indicated doses of KTN3379 or control IgG for 4 hours and then processed for ELISA analysis of pHER3 as indicated in Materials and Methods. Control represents untreated cells. B: BT474 cells were treated with the indicated doses of KTN3379 or control IgG for 4 hours and then processed for ELISA analysis of pAKT. Control represents untreated cells.

Xiao, Z., Carrasco, R. A., Schifferli, K., Kinneer, K., Tammali, R., Chen, H.,... & Tsui, P. (2016). A potent HER3 monoclonal antibody that blocks both ligand-dependent and independent activities: differential impacts of PTEN-status on tumor response. Molecular cancer therapeutics, molcanther-0555.

Figure 3 KTN3379 disrupts HER2-HER3 dimerization in both ligand-dependent and independent models.

Figure 3 KTN3379 disrupts HER2-HER3 dimerization in both ligand-dependent and independent models.

A: T47D cells were pre-treated with control IgG or KTN3379 and then treated with HRG to induce HER2/HER3 dimer formation as detailed in Materials and Methods. Cells were lysed HER3 immunoprecipitation was performed with anti-HER3 antibody that targets the cytoplasmic domain. The precipitates were run on Western Blots and probed for HER2 and HER3 proteins. The various lanes were cropped from the same Western Blot. B: BT474 cells were pre-treated with control IgG or KTN3379 and then treated with the cross-linker DTSSP to stabilize HER2-HER3 dimer prior to cell lysis as detailed in Materials and Methods. Cells were lysed and HER3 immunoprecipitation was performed with anti-HER3 antibody that targets the cytoplasmic domain. The precipitates were run on Western Blots and probed for HER2 and HER3 protein levels. The various lanes were cropped from the same Western Blot.

Xiao, Z., Carrasco, R. A., Schifferli, K., Kinneer, K., Tammali, R., Chen, H.,... & Tsui, P. (2016). A potent HER3 monoclonal antibody that blocks both ligand-dependent and independent activities: differential impacts of PTEN-status on tumor response. Molecular cancer therapeutics, molcanther-0555.

Figure 4 KTN3379 preferentially suppresses tumor growth in HRG-dependent models in vivo.

Figure 4 KTN3379 preferentially suppresses tumor growth in HRG-dependent models in vivo.

B, C: KTN3379 were tested in vivo for its anti-tumor effects in Lung adenocarcinoma model A549 (B) and Colorectal cancer model HT29 (D). Unless otherwise indicated, KTN3379 was dosed at 10 while control IgG was dosed at similar level or higher levels (30mg/kg). All mAbs treatment (twice per week) was started when tumor size reached ~250mm3.

Xiao, Z., Carrasco, R. A., Schifferli, K., Kinneer, K., Tammali, R., Chen, H.,... & Tsui, P. (2016). A potent HER3 monoclonal antibody that blocks both ligand-dependent and independent activities: differential impacts of PTEN-status on tumor response. Molecular cancer therapeutics, molcanther-0555.


Specifications

  • Immunogen
  • Human erb-b2 receptor tyrosine kinase 3
  • Host Species
  • Human
  • Type
  • Human IgG
  • Specificity
  • Human ERBB3
  • Species Reactivity
  • Human
  • Clone
  • KTN3379
  • Applications
  • ELISA, WB, IF, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The antibody was validated for Blocking, Inhibition and Functional Assay. For details, refer to published data.

Target

  • Alternative Names
  • ERBB3; erb-b2 receptor tyrosine kinase 3; HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; proto-oncogene-like protein c-ErbB-3; human epidermal growth factor receptor 3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3

Related Resources

  • Related Diseases
  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone KTN3379"

See other products for "ERBB3"

Single-domain Antibody

Humanized Antibody

CAT Product Name Application Type
TAB-892 Anti-Human ERBB3/ErbB 3 Recombinant Antibody (Seribantumab) IF, IP, Neut, FuncS, ELISA, FC, ICC IgG2 - lambda
TAB-H22 Anti-Human ERBB3 Recombinant Antibody (Duligotuzumab) (TAB-H22) ELISA, IP, FC, FuncS, Neut, IF, ICC IgG1 - kappa
TAB-057CT-F(E) Human Anti-ERBB3 Recombinant Antibody; Fab Fragment (TAB-057CT-F(E)) Inhibion, ELISA Humanized Fab
TAB-058CT-F(E) Human Anti-ERBB3 Recombinant Antibody; Fab Fragment (TAB-058CT-F(E)) WB, ELISA, Inhib Humanized Fab
TAB-059CT-F(E) Anti-Human HER3 Recombinant Antibody Fab Fragment (LMAb3) WB, ELISA, Inhibition, FC Humanized antibody

Immunotoxin

CAT Product Name Application Type
AGTO-L074E HRGβ2-PE immunotoxin Cytotoxicity assay, Functional assay

Chimeric Antibody

CAT Product Name Application Type
TAB-061CT Human Anti-ERBB3 Recombinant Antibody (TAB-061CT) Inhib, ELISA Chimeric (Rabbit/Human) antibody
TAB-061CT-S(P) Human Anti-ERBB3 Recombinant Antibody; scFv Fragment (TAB-061CT-S(P)) Inhib, ELISA Human scFv
TAB-061CT-F(E) Human Anti-ERBB3 Recombinant Antibody; Fab Fragment (TAB-061CT-F(E)) Inhib, ELISA Chimeric (Rabbit/Human) Fab

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-1179 Hi-Affi™ Rabbit Anti-ERBB3 Recombinant Antibody (clone DS1179AB) ICC, IF, WB Rabbit IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-H21 Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Duligotumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody
AFC-TAB-422CQ Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Elgemtumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, BL ADCC enhanced antibody
AFC-TAB-189 Afuco™ Anti-ERBB3 Recombinant Antibody (AFC-TAB-189), ADCC Enhanced IP, IF, FuncS, FC, Neut, ELISA Human IgG1, κ
AFC-TAB-H22 Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Duligotuzumab), ADCC Enhanced ELISA, IP, FC, FuncS, Neut, IF ADCC enhanced antibody
AFC-TAB-892 Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Seribantumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for PABL-086. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare